Background: Progress in the diagnosis, localization of abnormal parathyroids, and intraoperative management of primary hyperparathyroidism has been observed over the past 34 years. The goal of this study is to report the outcome of patients undergoing 2 different operative approaches in a single institution, showing the evolution of surgical management of sporadic primary hyperparathyroidism (SPHPT). Methods: Parathyroidectomy was performed in 890 (827 initial, 63 reoperative) patients with SPHPT using 2 different approaches: traditional bilateral neck exploration (BNE, n ϭ 396) or limited parathyroidectomy guided by parathormone dynamics (LPX, n ϭ 494). Seven hundred eighteen patients (335 BNE, 383 LPX) followed Ն 6 months or identified as operative failures were studied. Operative failure is defined as hypercalcemia and high intact (1-84) parathyroid hormone molecule (iPTH) within 6 months after operation. Successful parathyroidectomy is normocalcemia for 6 months; hypercalcemia and elevated iPTH after this time is recurrent hyperparathyroidism. Results: There were 20 (6%) of 335 operative failures in the BNE group and 11 (3%) of 383 failures in the LPX group (P ϭ 0.04). The incidence of multiglandular disease (MGD) determined by gland size (10%) versus hormone hypersecretion (3%) was statistically different (P Ͻ 0.001). Since most of the recurrences occurred later than 30 months, the incidence of recurrent hyperparathyroidism in patients followed for longer than 2.5 years was 4% (11/287) in the BNE group (average, 11.5 years) and 3% (5/183) in the LPX group (average, 4.2 years). Conclusion: LPX, with its reported advantages of minimal dissection, shorter operative time, and use in ambulatory settings, compares favorably with the traditional BNE. Parathyroidectomy guided by parathormone dynamics has an improved success rate and should be considered as a standard operative approach in SPHPT.
T he past 34 years have seen major advances in the operative management of sporadic primary hyperparathyroidism (SPHPT). The widespread use of biochemical autoanalyzers helped call early attention to serum calcium imbalances that, if left unresolved, were associated with severe bone and kidney diseases. Surgeons called on to treat these patients expanded the operative indications to manage this disease in a much earlier state. In asymptomatic patients without demonstrable defects in the main target organs, the diagnosis of SPHPT was often challenging and occasionally resulted in unsuccessful parathyroidectomy with the patient remaining either hypercalcemic or experiencing permanent tetany.
A major advance in diagnostic accuracy of SPHPT occurred in 1968 when Reiss and Canterbury 1 first described a parathyroid hormone (PTH) antibody that had good affinity for the hormone in humans and could be measured with an immunoradiometric PTH assay. Diagnostic ability improved, but this early assay measured only a part of the parathormone molecule, which limited its usefulness. In 1988, Nussbaum et al. 2 described a new method for measuring the intact (1-84) parathyroid hormone molecule (iPTH) by using a 2-site antibody technique that proved to be more sensitive and specific. Ten years ago, this assay changed from radionuclear to immunochemiluminescent technology using a light source for measurement of the hormone. This made the assay practical for intraoperative, point-of-care use.
Another major advance in the management of SPHPT was seen in preoperative localization of abnormal glands. Although several invasive and noninvasive methods have been tried, the 2 most useful are ultrasonography, which is operator-dependent, and nuclear scanning, which has the advantage of allowing visualization of cervical and thoracic images easily taken to the operating room for anatomic review during parathyroidectomy. 3 Progress in operative guidance has been seen with the use of a rapid intraoperative iPTH assay (QPTH), which confirms the complete excision of all hyperfunctioning parathyroid tissue or alerts the surgeon of an incomplete excision, indicating the need for further exploration to achieve a successful parathyroidectomy. Since first described in 1991, rapid intraoperative iPTH assay became commercially available in 1996 and is now used as a surgical adjunct in over 100 institutions around the world. 4, 5 The purpose of this study is to compare the outcomes of consecutive patients with SPHPT undergoing 2 different operative approaches to parathyroidectomy over a 34-year period in a single institution.
METHODS
Eight hundred ninety consecutive patients with SPHPT undergoing parathyroidectomy in our institution from 1969 through 2003 were studied. Eight hundred twenty-seven patients had their initial neck exploration performed at the University of Miami, and 63 had reoperative parathyroidectomies for either recurrent disease or a failed parathyroid procedure at another institution. Patients with secondary, tertiary, familial hyperparathyroidism (HPT), or history of multiple endocrine neoplasia (MEN) were not included in this study.
Since 1972, all preoperative patients had their serum parathormone levels measured as part of their diagnostic work-up. The diagnosis of SPHPT was defined as hypercalcemia, elevated iPTH, normal renal function, and no familial history of HPT or MEN.
From 1969 through August 1993, the operative approach used in all patients was bilateral neck exploration (BNE) with visualization of all parathyroids and resection of all enlarged glands on the basis of the surgeon's interpretation of gland size. Histopathology was performed only to confirm parathyroid tissue. When more than 1 enlarged gland was resected, the patient was considered to have multiglandular disease (MGD). If one enlarged gland was resected and persistent postoperative hypercalcemia occurred, this patient was considered to have MGD as well.
In September 1993, the operative approach changed to limited parathyroidectomy (LPX), in which the parathyroid resection is guided by intraoperative iPTH levels measured by a rapid hormone assay and assisted by preoperative localization studies. Tc-99m-sestamibi nuclear scan (Dumont Merck Pharmaceutical Co., Billerica, MA) was routinely used for the last 10 years with a SPECT scan obtained in most patients. Surgeons have performed cervical ultrasounds in all patients for the past 2 years.
We have used the immunochemiluminescence intraoperative iPTH assay (Nichols Institute Diagnostics, San Juan Capistrano, CA; and Future Diagnostics, Wijchen, Netherlands) in all patients with SPHPT as a surgical adjunct to predict postoperative calcium levels, localize hard-to-find glands, identify MGD, and to assure the surgeon when all hypersecreting parathyroid tissue has been excised. All patients with clear indications for operative intervention, as outlined in the 1991 NIH Consensus Report or as suggested by our group in 2000, were offered LPX guided by QPTH whether localization studies were positive or not. 6, 7 Patients with negative or equivocal preoperative localization tests were also included in the LPX group with differential jugular venous sampling of hormone levels in the operative room used to guide the surgeon to the probable side of the abnormal gland. 8 The technical aspects of the assay and the intraoperative criterion have been recently described. 8, 9, 10 Briefly, a drop Ն 50% from the highest either pre-incision (obtained just before the skin incision) or pre-excision (obtained just before clamping the gland's blood supply) peripheral iPTH level 10 minutes after the excision of a suspected parathyroid gland signaled that all hypersecreting tissue had been removed. If a significant drop in hormone did not occur, further exploration and excision was done with the criterion repeated for each excision until all hyperfunctioning parathyroid glands were removed. If the hormone drop was sufficient to predict complete resection and postoperative normocalcemia, the procedure was finished without further exploration and visualization or biopsy of the remaining glands. Patients with more than 1 gland excised when guided by QPTH at the same procedure were considered to have MGD. If persistent hyperparathyroidism occurred after a single gland excision, the patient was considered to have MGD as well. Successfully treated patients who developed recurrence are not considered to have MGD.
The outcomes of consecutive patients with SPHPT undergoing parathyroidectomy by 2 different operative approaches were compared. Among 890 patients operated between 1969 through 2003, 718 had Ն 6 months of follow-up or were identified as operative failures. Three hundred thirtyfive (317 initial, 18 reoperative) patients had a traditional BNE with resection guided by gland size and/or histopathology. The second group (1993 to 2003) comprised 383 (346 initial, 37 reoperative) patients who underwent LPX in which the resection was exclusively guided by intraoperative PTH dynamics.
Serum calcium and iPTH levels were carefully monitored in the immediate postoperative period, at 2 and 6 months after the operation, and then at yearly intervals. Operative success was considered to be normocalcemia for at least 6 months after the operation. Operative failure was defined as high serum calcium and iPTH (above normal range for the laboratory) occurring within 6 months after parathyroidectomy. Recurrent hyperparathyroidism was defined as an elevated serum calcium and high iPTH found later than 6 months after a successful parathyroidectomy. One hundred forty-one patients with insufficient follow-up (Ͻ6 months), even though normocalcemic in the immediate postoperative period, were not included in this evaluation because of the inability to determine the operative outcome. All known operative failures are included in this study whether or not they were followed for a 6-month postoperative period. The outcomes were statistically compared by 2 text and considered significant when P Ͻ 0.05.
RESULTS
Among 718 patients with SPHPT followed Ն 6 months or considered as operative failures, 335 with BNE had a success rate of 94%, with 20 (6%) patients identified as operative failures. Parathyroidectomy guided by surgeon's judgment of gland size resulted in an incidence of MGD of 10%. The average follow-up of the BNE group was 10 years (6 to 409 months). Recurrent HPT was found in 11 (4%) patients diagnosed between 7 and 100 postoperative months.
In the group with LPX, operative success was 97%, with 11 (3%) of 383 patients identified as operative failures. Successful parathyroidectomy was achieved with unilateral neck exploration in 90% of the LPX group of patients. The resection guided exclusively by QPTH provided operative success with multiple gland involvement in only 3% of the patients. The intraoperative iPTH assay recognized 10 (83%) of 12 patients with multiglandular disease. In 8 of 10 patients, the QPTH guided the surgeon to operative success with identification of multiple gland involvement. In the other 2 patients, despite QPTH pointing out MGD, persistent hypersecreting tissue could not be found, resulting in operative failure. In 2 of 12 patients, QPTH did not recognize MGD (false positive result). The average follow-up period of this group was 3 years (6 to 105 months). Recurrent HPT occurred in 5 patients (3%) and was diagnosed between 24 and 83 months. QPTH did not predict intraoperatively the late recurrence in these patients. The rapid intraoperative assays and our criterion used to predict complete resection and postoperative calcium levels for 6 months had sensitivity, specificity, and overall accuracy rates of 97%, 96%, and 97%, respectively.
The operative success rate is statistically different between the 2 groups (P ϭ 0.04), with LPX showing the higher rate. The incidence of MGD was different in the 2 groups on the basis of the 2 different methods of identification of gland abnormality. Patients undergoing LPX had 7% less multiple gland disease identified than the BNE group (P ϭ 0.001). Although there is a shorter follow-up period in the LPX group, there is no difference in the recurrence rate between the 2 groups.
In an attempt to more accurately evaluate late recurrence after parathyroidectomy, patients from both groups with longer follow-up intervals were closely studied. Since most of the recurrences occurred later than 30 months after parathyroidectomy, the outcomes of 287 patients with BNE and 183 with LPX followed for more than 2.5 years were reviewed. The incidence of recurrent HPT in the BNE group was 4%, with an average of 11.5 years follow-up and 3% in the LPX group followed for an average of 4.2 years.
DISCUSSION
In recent years, the trend toward less invasive surgery has been accepted and required by patients and physicians in the management of many disorders. This has included treatment of primary HPT in which new adjuncts have allowed surgeons more accurate diagnosis, better anatomic localization of involved glands, and intraoperative quantitative assurance as to when all hypersecreting glands have been removed. Utilization of these adjuncts has resulted in "limited" parathyroidectomy. The advantages of this operative approach include unilateral neck dissection, excision of only hypersecreting glands, small incisions, short operating times, local or light general anesthesia, and ambulatory surgery. However, to justify a change in parathyroidectomy using BNE with excision of all enlarged glands, the operative success rate of a limited approach must be equal to or better than reported with the traditional procedure.
When the 2 surgical approaches are compared, we show that the operative success rate has significantly improved with the use of the surgical adjuncts used in the LPX group. This has been difficult to demonstrate in the literature because of the excellent success rates reported by many surgeons from the larger clinics using the traditional BNE approach in parathyroidectomy. With sufficient patient numbers generated using the LPX approach over the past 10 years, the improved outcome can now be shown by comparing patients in a single institution. 11 The incidence of MGD in SPHPT has been reported to be as high as 30% and is often quoted to be 14 to 24%. [12] [13] [14] [15] Our finding of only 3% MGD in patients undergoing LPX has been recently questioned by Haciyanli et al, 16 who suggest that selection of patients on the basis of positive preoperative localization studies may be the reason for such low incidence of MGD. However, it is our practice that all patients with a secure diagnosis of SPHPT and established operative indications have LPX whether preoperative localization studies were positive or not. Although the great majority of patients in the LPX group had preoperative Tc-99m-sestamibi scans, 5% of the scans were found to be negative and 13% were equivocal. We found that iPTH levels from differential jugular venous sampling before the skin incision often pointed out the correct side harboring the abnormal gland, thereby allowing a successful parathyroidectomy with unilateral neck exploration in this group of patients with negative or equivocal scan results. 8 Several other investigators claim that their intraoperative hormone assay did not recognize "double adenomas" or MGD. For example, Haciyanli et al 16 reported that 12 of 21 patients in their series showed an adequate decrease in hormone level after excision of a single hypersecreting gland, but they claimed that further exploration revealed another adenoma that was removed, suggesting the QPTH gave false positive results and missed these "second adenomas." Others have reported similar findings with a high incidence of QPTH false positive results based on excision of a single hypersecreting gland shown by an adequate hormone drop followed by continued exploration and the finding of another large gland that was then resected. 12,15,17-21 Investigators who claim QPTH did not identify the second enlarged gland, and therefore failed to show MGD, have no evidence that the second gland was hyperfunctioning and contributing to the hyperparathyroid state. Moreover, if we assume that 14 -30% of SPHPT patients have enlarged glands and the so-called "second adenoma" or MGD and these glands are left in situ and not even visualized in our LPX patients, then we should expect a much higher operative failure rate than reported in this group of patients. In our LPX group, the early operative success rate and low recurrence rate at 4 years suggest that many of the glands excised in the BNE group on the basis of size alone were and continued to be normally functioning parathyroid glands not contributing to the HPT. The sample timing and dynamic changes in the hormone levels during parathyroidectomy are critical to making accurate predictions of postoperative calcium levels by QPTH. The assay itself measures only iPTH in the plasma at the point when the sample is acquired. Other investigators have proposed several criteria for this test with varying degrees of accuracy. We have found that the criterion used in the LPX group in this study predicts outcome better than the other published methods. We have shown that QPTH using our criterion has excellent sensitivity, specificity, and an overall accuracy in predicting postoperative calcium levels of 97%. 9 Several authors have reported that patients have elevated iPTH levels and normocalcemia after parathyroidectomy. [22] [23] [24] [25] [26] We have found that the incidence of elevated iPTH with normocalcemia is the same in both the BNE and LPX groups. 26 We agree with Bergenfelz et al 22 and Carty et al 25 when they suggest that this elevated iPTH level with normocalcemia is most probably a physiological response to an overall body calcium deficit. Carty et al 25 have reported and we have confirmed that most of these postoperative patients will respond to exogenous calcium supplementation with a decrease in the iPTH level while remaining normocalcemic, confirming that these parathyroid glands are not autonomous.
Another question that invariably comes up is the cost of these surgical adjuncts. Udelsman 27 has reported that the cost of intraoperative hormone measurement and nuclear scanning in his hospital is cost-effective, but many clinical pathology departments do not wish to bear the cost of intraoperative hormone assays in their local budgets. Hospital administrators should assume a major role in justifying the added cost of these techniques. The major saving is in the ability to do these procedures on an outpatient basis. 27-29 More than 70% of our patients are eligible for same-day surgery without admission or an overnight stay in the hospital. This is a real cost saving and should be considered when looking at the costs of these scans and intraoperative assays.
No surgeon wants to have an unsuccessful outcome and be unable to correct the problem of hypercalcemia in a patient with hyperparathyroidism. No patient wants to recover from a parathyroidectomy and have persistent disease. Three modalities have become available over the last 34 years that changed the management of SPHPT. This disease is now more successfully treated using these surgical adjuncts than in previous years, when quantitative assessment of abnormal parathyroid tissue was not available.
CONCLUSION
Over the past 34 years, 3 major technical advances have changed the operative management of patients with sporadic primary hyperparathyroidism: the ability to measure parathyroid hormone makes the diagnosis of SPHPT secure in patients presenting with hypercalcemia; ultrasonography and Tc-99m-sestamibi nuclear scans help with preoperative localization of abnormal glands; and the intraoperative iPTH assay, with an accurate criterion for interpreting hormone dynamics, guides the parathyroid procedure by predicting outcome. The incorporation of these surgical adjuncts over the past 10 years has improved our operative success rates compared with the traditional parathyroidectomy with BNE used previously. We suggest that limited parathyroidectomy be considered as a standard operative approach in patients with sporadic primary hyperparathyroidism. 
Discussions
DR. GEORGE S. LEIGHT, JR. (Durham, North Carolina): Dr. Irvin and his co-authors are again to be congratulated for another fine contribution to the ever-increasing body of information supporting the use of intraoperative PTH as an important adjunct in the operative management of our patients with sporadic primary hyperthyroidism. Dr. Irvin has been instrumental in the development and establishment of the concept of intraoperative PTH, and I certainly acknowledge that he kindled my interest in this area leading to our own successful series in approximately 350 patients at Duke. It is quite remarkable how similar our results have been over the years to those of Dr. Irvin and his group. There are 2 very important points I think that come out of this report.
A criticism from some of the experienced parathyroid surgeons over the years has been that intraoperative PTH will give misleading results in patients with multiple gland disease because of the possibility of differential set points for different multiple abnormal glands. It is important that this was not the case in 83% of his patients with multiple gland disease. This is also similar to our own results.
Another criticism of limited neck exploration is that the long-term recurrence rates will be higher than with bilateral neck exploration because of missed abnormal glands. That problem has not been apparent in this experience. And as Dr. Irvin just showed you only a 3% recurrence rate at a 4.2-year follow-up, certainly one would expect that this would start to become more obvious if it were going to be a long-term problem by this time.
Are there significant weaknesses in this report? The quite obvious one is that it is not a randomized prospective study but rather a retrospective study using historical control groups. There are some problems comparing the patient undergoing bilateral neck exploration in 1969 to the patient having a limited exploration in 2003. And this raises some difficult issues.
First, we may be comparing apples and oranges here since the patient population of hyperparathyroid patients in the '60s and '70s was probably different as far as being symptomatic, having other problems such as bone disease, compared to the current patient population in which 70% to 80% are asymptomatic. The current availability of intact PTH assays, as Dr. Irvin has reviewed, assures the diagnosis of hyperparathyroidism in our current patient population. There may be other factors as well, which make comparison to historical controls difficult.
There have been attempts to examine this issue in a randomized prospective fashion but they have suffered from small patient numbers. A large randomized study would be difficult, I think, to organize. However, it may be somewhat of an over interpretation of these data to conclude that "the operative success rate has significantly improved with the utilization of surgical adjuncts used in the limited parathyroidectomy group." I would ask Dr. Irvin, is it now possible, or in your opinion necessary, to carry out a larger randomized prospective multi-institutional study to answer the questions in a more definitive manner? Also, in the manuscript you mentioned obtaining bilateral jugular vein PTH values in patients without preoperative localization. Can you give us an indication of how successful this has been in predicting the location of the size of the abnormal gland?
Dr. Irvin is to be congratulated for his leadership and important contributions to the management of our patients with primary hyperparathyroidism. We at Duke continue to be enthusiastic about the superiority of this limited parathyroidectomy approach in our own patients with sporadic primary hyperparathyroidism.
DR. NANCY PERRIER (Winston-Salem, North Carolina):
Dr. Irvin has succinctly presented an insightful review of the operative management of spontaneous primary hyperparathyroidism over the past three and a half decades.
The 3 major advances of improved diagnostic measurement-the intact PTH molecule, the physiologic radioisotopes that image the mitochondria of abnormal parathyroid glands, and the ability to utilize intraoperative analysis of the parathyroid hormone, have significantly altered the surgical approach to this disease. Dr. Irvin's previous work has greatly facilitated this international advance.
This large review of the surgical experience at a single institution is important because it compares 383 cases performed between 1993 and 2003 to 335 cases performed between 1969 and 1992. The real comparison of these 2 cohorts is between the surgeon's judgment of the size of the glands to the actual PTH dynamics of hypersecretion. This comparison addresses the important question of whether all enlarged glands actually hypersecrete. These data demonstrating a similar recurrence rate despite a significantly lower incidence of multigland disease noted with the limited approach, suggests, no, large glands do not all over secrete.
Another important factor that deserves attention is the excellent patient selection used by Dr. Irvin and his group. The identification of the MEN syndrome in the 1980s, the gene identification in the 1990s, and the recognition of familial isolated hyperparathyroidism as recently as 1999 undoubtedly reinforces the recognition of a large group of patients that are ineligible for this localized procedure because of their known and expected multiglandular disease. It might be assumed that in the first decade or 2 of this work that the exclusion of these patients was not possible thus, these cases were included as being spontaneous primary hyperpara-thyroid patients and underwent bilateral neck explorations, at which time multigland disease was identified.
This excellent paper reinforces 3 concepts: One, the importance of good patient selection. Two, the probability that not all enlarged glands hypersecrete. And 3, recent technology combined with good judgment and surgical skill enhance our surgical successes.
I have 3 questions for Dr. Irvin. First, was there a difference in the rate of the long-term tetany and aparathyroidism in your bilateral neck exploration group with multigland disease versus those that underwent limited parathyroid exposure? This is important since the real risk in performing a subtotal parathyroidectomy is the risk of longterm hypoparathyroidism. We assume that this must be low or negligible in the limited exploration group at which time the glands were not likely to be devascularized.
Second, do you have access to the weights of the glands in the multigland disease noted in that bilateral neck exploration group? Were they all truly and objectively enlarged, or were they believed to be enlarged and abnormal because of our previous subjective eyeball test?
And third, do you have plans to present a sequelae including those long-term results of that 16% of patients that were lost to follow-up? DR. WILLIAM R. NELSON (Denver, Colorado): I appreciate the opportunity to discuss this remarkable paper. As a guest of the Southern Surgical Association, I would like to give one brief case report illustrating a rather rare form of hyperparathyroidism and then tell of the discussion of a paper on another subject given to the Association in 1895.
I want to ask Dr. Irvin a question. Have you treated cases of cancer of the parathyroid? We recently had a case that was rather spectacular, with a highly malignant tumor of one gland and hyperplasia of the remaining glands. One of these glands with hyperplasia actually had an in situ carcinoma. It was almost like a progression from benign hyperplasia into in situ carcinoma into invasive cancer. This was resected successfully with very close margins. Recurrence is likely. Is this a rather rare phenomenon?
Then I would like to bring up that bit of history. Hugh Nelson of Charlottesville, my grandfather, a member of the Southern Surgical, 108 years ago, discussed a paper at the 8th Annual Meeting of the Association. This was on a different subject, trauma of the abdomen. Operative Management of Sporadic Primary Hyperparathyroidism importance of intraoperative parathyroid hormone monitoring, which I certainly agree is the most important adjunct to a limited parathyroidectomy. I have 3 brief questions. The first question pertains to the criteria for successful parathyroidectomy in terms of whether or not the parathyroid hormone level needs to fall only by 50% or within the normal range. In our experience at Washington University, even if the parathyroid hormone level falls by more than half at 10 minutes, if it doesn't fall to the normal range we have had some operative failures.
Second, I would like you to address whether or not it makes a difference whether the parathyroid hormone level is drawn through the neck incision in the enteral jugular vein or peripherally and whether that changes the criteria for a successful surgery.
Finally, of the 2 concerns of a minimal approach, one would be missing multiglandular disease and the other would be an increased risk of injury to the recurrent nerve. You didn't address that in the 2 groups.
DR. MICHAEL ROE (Chattanooga, Tennessee): Dr. Irvin, once again I enjoyed your paper, as I always do. It does raise a couple of questions for me.
Along with the 97% accuracy of intraoperative PTH in your hands, most of us would feel this is a very low incidence of multigland disease, 3%. Is intraoperative PTH monitoring as accurate in that group of multigland disease as in the vast majority of the patients, who proved to have single gland disease, or, if you look at it another way, in the patients who have a positive preoperative localization study. Or, as some of us might do, a Sestamibi scan surgeon-performed ultrasound and have a combination where you find concordant preoperative studies and then intraoperatively you find a large gland in that spot? If you have such a low incidence of multigland disease, how often does your intraoperative PTH change only confirm what you already know that you were done? How often does it lead you to further exploration that is necessary, like in the one example you showed, or does it occasionally lead you to further exploration that may be unwarranted?
DR. RICHARD E. GOLDSTEIN (Louisville, Kentucky): I rise to thank Dr. Irvin for choosing to submit a group of patients and a life-long body of work to this Association to be presented at this meeting. Certainly the changes in imaging and the use of the quick PTH tool I think has contributed to the increased rate of success in the patients that Dr. Irvin has taken care of. I think both of those tools have been major advantages to us.
But I also want to raise one other issue, or one other possibility, that may have contributed to the better rates of success that Dr. Irvin's patients experienced over the last 8 years, and that is that Dr. Irvin had a lot more experience.
And that experience ends up making you a much better surgeon and a master surgeon at this. And I think that is a factor that is difficult to separate out. And I thank you very much, Dr. Irvin DR. GEORGE L. IRVIN, III (Miami, Florida): There were 3 questions that had to do with localization. We obtained sestamibi scans on everybody, and for the last 2 years, we have been doing surgeon-directed ultrasonography. As far as the scan is concerned, most of them are done with SPECT. We had a 5% absolutely negative scan in these patients and 13% were equivocal scans that turned out to be false positive/ false negative when correlated with operative findings. In this group of patients, the ultrasound does help us a lot by determining whether the positive part of the scan is a thyroid nodule or a parathyroid. If we have a negative scan, before the incision is made, we get bilateral blood sampling from the jugular vein and give it to the assay person right there in the operating room for differential PTH levels. In 8 minutes, we will know which side to go to about 70% of the time. We have found that to be quite helpful with a PTH step up on the involved side. You do this any time during the operation if you have a difficult patient with a hard to find gland.
Another trick that Orlo Clark and Nancy Perrier wrote about is finding a piece of tissue that may or may not be thyroid, parathyroid, or lymph node. If you don't know what it is, you take a little 25-gauge needle, put it right into that tissue, dilute the sample with a cc of saline, and do a hormone assay on it. If it is parathyroid tissue, the hormone level will be up in the thousands. If it is thyroid or lymph node or something else, it will not. That is a very specific way of helping the surgeon identify the abnormal or unknown tissue. It is a whole lot faster than doing a biopsy and calling for a frozen section.
Dr. Leight asked about randomized studies. No, I don't think we are ever going to do a randomized study on this. We don't have that many patients, and I just don't think we need to. The results from those people who do bilateral necks are excellent with a reported 90% to 98% success rate in the big clinics. We have a good success rate also. So I don't think there is going to be a need for a randomized study in the future.
Dr. Perrier asked about the large glands and tetany. The only time we have had permanent tetany in the last 10 years is when we have a reoperative patient where some surgeon couldn't find the abnormal gland, took out 3 normal glands, and then the patient comes to us with hypercalcemic crisis or calcium levels up around 13 with marked symptoms. We operate on the patient and take out the missed tumor. With 3 patients like this in our series, it is the worst nightmare you can have. You know you are going to end up with permanent tetany. Despite transplantation and freezing the gland with retransplanting and everything else, sometimes it just doesn't work. Other than that situation, we don't have any permanent tetany in the multiglandular group. Dr. Bergenfelz recently reported lower calcium levels requiring more exogenous calcium in the immediate postoperative period in his BNE patients compared to LPX patients in a controlled, randomized study (Ann Surg 236:543), but this was not permanent tetany.
We don't measure the excised glands by weight. We measure the three dimensions of the gland. We have not looked at the weights of the removed tumors. This is an ongoing study. We have 141 patients, Dr. Perrier, who had immediate postoperative eucalcemia. However, they haven't been followed 6 months. We are continuing to do that, and hopefully, it is just going to make us look better when they come on line after 6 months.
Dr. Nelson asked about cancers. Yes, we have had 5 diagnosed cancers in these 850 patients. Four of them were operated on as sporadic primary hyperparathyroidism. The cancers were not recognized at the time. The assay showed us that we had cured these patients as far as removing all hypersecreting glands, but they had a recurrence, which the assay did not predict. One other patient not included in this series was on dialysis. He had multiglandular disease and hyperplasia with cancer found in one of his glands.
Dr. Lairmore asked about our criteria. That was discussed and presented at the AAES meeting last spring and will be published this month (Surgery 134:973) comparing the different criteria that have been used to evaluate the assay. I think the criterion we use comes out pretty good. We don't make the hormone level go all the way down, we use a dynamic fall for significance. If the PTH level drops 50% or more from the highest level, we are pretty accurate in predicting the postoperative calcium.
There are 2 groups in the country, 1 in Atlanta under Dr. Weber and 1 in San Francisco under Dr. Clark, which have been the naysayers about the use of the quick assay. These investigators report too many false positives with the assay. What they do is they go in, find the abnormal gland, take it out, and the hormone falls like it is supposed to. Ordinarily in Miami, we would just close the patient and go home. But they keep looking despite the significant hormone drop. They open the other side of the neck and do a bilateral neck exploration. They report that 14% to 30% of their patients have other big glands. They then take them out saying the assay missed a second adenoma and suggesting the test is not any good because it gives too many false positives.
Well, we disagree with that. And I think our data today will show why. We have about 17% less multiglandular disease than anybody else. And yet, we have an excellent operative success rate, and at 4 years, an equal recurrence rate. The size of the gland or glands does not correlate with hypersecretion. With the intraoperative iPTH assay, we are looking at hyperfunction or hypersecretion of glands. That is what we are treating and not just the size of the parathyroid glands. We think if you remove glands just based on size, you are often unnecessarily excising normally functioning parathyroids.
